Involvement of Allosteric Effect and $K_{\text{Ca}}$ Channels in Crosstalk between $\beta_2$-Adrenergic and Muscarinic M$_2$ Receptors in Airway Smooth Muscle

Hiroaki Kume$^{1,*}$, Osamu Nishiyama$^1$, Takaaki Isoya$^1$, Yuji Higashimoto$^1$, Yuji Tohda$^1$ and Yukihiro Noda$^2$

$^1$ Department of Respiratory Medicine and Allergology, Faculty of Medicine, Kindai University, 377-2 Ohnohigashi, Osakasayama 589-8511, Japan; nishi-o@med.kindai.ac.jp (O.N.); solution.management27@gmail.com (T.I.); yhigashi@med.kindai.ac.jp (Y.H.); tohda@med.kindai.ac.jp (Y.T.)

$^2$ Division of Clinical Sciences and Neuropsychopharmacology, Graduate School of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya 468-8503, Japan; y-noda@med.nagoya-u.ac.jp

* Correspondence: hkume@med.kindai.ac.jp; Tel.: +81-72-366-0221 (ext. 3602); Fax: +81-72-367-7772

Received: 23 March 2018; Accepted: 4 July 2018; Published: 9 July 2018

Abstract: To advance the development of bronchodilators for asthma and chronic obstructive pulmonary disease (COPD), this study was designed to investigate the mechanism of functional antagonism between $\beta_2$-adrenergic and muscarinic M$_2$ receptors, focusing on allosteric effects and G proteins/ion channels coupling. Muscarinic receptor antagonists (tiotropium, glycopyrronium, atropine) synergistically enhanced the relaxant effects of $\beta_2$-adrenergic receptor agonists (procaterol, salbutamol, formoterol) in guinea pig trachealis. This crosstalk was inhibited by iberitoxin, a large-conductance Ca$^{2+}$-activated K$^+$ channel inhibitor, whereas it was increased by verapamil, a L-type voltage-dependent Ca$^{2+}$ channel inhibitor; additionally, it was enhanced after tissues were incubated with pertussis or cholera toxin. This synergism converges in the G proteins ($G_i$, $G_s$)/$K_{\text{Ca}}$ channel/VDC channel linkages. Muscarinic receptor antagonists competitively suppressed, whereas, $\beta_2$-adrenergic receptor agonists noncompetitively suppressed muscarinic contraction. In concentration-inhibition curves for $\beta_2$-adrenergic receptor agonists with muscarinic receptor antagonists, EC$_{50}$ was markedly decreased, and maximal inhibition was markedly increased. Hence, muscarinic receptor antagonists do not bind to allosteric sites on muscarinic receptors. $\beta_2$-Adrenergic receptor agonists bind to allosteric sites on these receptors; their intrinsic efficacy is attenuated by allosteric modulation (partial agonism). Muscarinic receptor antagonists enhance affinity and efficacy of $\beta_2$-adrenergic action via allosteric sites in $\beta_2$-adrenergic receptors (synergism). In conclusion, $K_{\text{Ca}}$ channels and allosterism may be novel targets of bronchodilator therapy for diseases such as asthma and COPD.

Keywords: synergistic effects; G protein; large-conductance Ca$^{2+}$-activated K$^+$ channels; L-type voltage-dependent Ca$^{2+}$ channels; $\beta_2$-adrenoceptor agonists; muscarinic receptor antagonists; asthma; COPD

1. Introduction

Since the functional antagonism between $\beta_2$-adrenergic and muscarinic receptors regulates airway smooth muscle tone, investigation of this antagonism may play a key role for progressing bronchodilator therapy for asthma and chronic obstructive pulmonary disease (COPD) [1–4]. Airway smooth muscle generates tension via Ca$^{2+}$ signaling, which consists of an increase in intracellular concentration of Ca$^{2+}$ (Ca$^{2+}$ dynamics) and an increase in sensitivity to intracellular Ca$^{2+}$ (Ca$^{2+}$ sensitization) [5–11]. Potassium ion (K$^+$) channels also contribute to smooth muscle...
tone via Ca\(^{2+}\) signaling [12–15]. Ca\(^{2+}\) dynamics may be associated with GTP-binding (G) proteins (G\(_{s}\), G\(_{i}\))/large-conductance Ca\(^{2+}\)-dependent K\(^{+}\) (K\(_{Ca}\)) channels/L-type voltage-dependent Ca\(^{2+}\) (VDC) channel linkage, leading to Ca\(^{2+}\)-dependent contraction [1,2,16,17]. Hence, K\(_{Ca}\) channels may be responsible for therapeutic strategies for various diseases, including asthma and COPD [4,18–20].

The combination of \(\beta_2\)-adrenergic receptor agonists with muscarinic receptor antagonists markedly enhances relaxant effects on muscarinic contraction [4,11,21]. This effect is due to crosstalk between \(\beta_2\)-adrenergic and muscarinic receptors (G protein-coupled receptors: GPCRs), and is also involved in Ca\(^{2+}\) signaling mediated by K\(_{Ca}\) channels [4,11] and protein kinase C (PKC) [22–24]. The recent COPD guidelines state that a combination of bronchodilators of different pharmacological classes may improve effectiveness and decrease the risk of adverse reactions, compared to increasing the dose of a single bronchodilator [25]. There is a pharmacological rationale for combining \(\beta_2\)-adrenergic receptor agonists and muscarinic receptor antagonists as a bronchodilator therapy for asthma and COPD [4,11,21,24,26]. Clinical trials have indicated that this combination therapy is beneficial to these diseases [27–29].

Both orthosteric and allosteric sites exist on GPCRs, and the effects of an agent (an orthosteric ligand) are influenced (potentiated or inhibited) via allosteric effects. An agonist binds to GPCRs as an allosteric modulator at an allosteric site, which is topographically distinct from an orthosteric site, leading to changes in response to an agent via an alteration in receptor conformation. Hence, allosteric GPCR modulation provides pharmacological characteristics, such as affinity, efficacy, and agonism [30,31]. Since allosteric effects may occur in the interaction mediated by ligands for GPCRs [30–32], allosteric GPCR modulation may contribute to the synergistically relaxant effects of the combination of \(\beta_2\)-adrenergic receptor agonists with muscarinic receptor antagonists against muscarinic contraction in airway smooth muscle. As shown in a recent report [4,15], allosteric GPCR modulation is involved in the alteration of responsiveness to \(\beta_2\)-adrenergic action against muscarinic contraction. However, little is known about the particular role of allosterism in the functional antagonism between \(\beta_2\)-adrenergic and muscarinic receptors.

This study was designed to determine involvement of K\(_{Ca}\) channel/VDC channel linkages in the synergistic effects between \(\beta_2\)-adrenergic receptor agonists and muscarinic receptor antagonists. Moreover, the role of allosteric GPCR modulation in this synergism was investigated using physiological techniques in airway smooth muscle.

2. Results

2.1. Synergism in the Combination of \(\beta_2\)-Adrenergic Receptors with Muscarinic Receptor Antagonists

Tiotropium (1 nM) caused a modest inhibition (5.9 ± 1.3%, \(n = 8\)) [95% CI: 4.81–6.99] of methacholine (MCh, 10 \(\mu\)M)-induced contraction (Figure 1A,B). Procateterol (10 nM) caused a 52.2 ± 6.9 percent inhibition [95% CI: 46.43–57.97] of MCh (10 \(\mu\)M)-induced contraction (\(n = 8\)) (Figure 1A,B). When procateterol (10 nM) was applied to the tissues pre-contracted by MCh (10 \(\mu\)M) in the presence of tiotropium (1 nM), the inhibitory effects of the combination of procateterol and tiotropium were markedly enhanced (Figure 1A), and values of percent inhibition increased to 80.8 ± 9.0% [95% CI: 73.27–88.33] (\(n = 8\), Figure 1B). Under this experimental condition, the values of percent inhibition were considerably greater than the values of percent inhibition predicted by the Bliss independence (BI) theory (55.1 ± 5.9%, 95% CI: 50.17–60.03, \(n = 8\), \(p < 0.01\); Figure 1B). Similar results were observed for salbutamol and tiotropium. Salbutamol (100 nM) caused a 44.1 ± 6.2 percent inhibition [95% CI: 38.92–49.28] of MCh (10 \(\mu\)M)-induced contraction (\(n = 6\), Figure 1C). When salbutamol (100 nM) was applied in the presence of tiotropium (1 nM), the inhibitory effects of the combination of salbutamol and tiotropium were markedly enhanced (Figure 1A), and values of percent inhibition were increased to 80.8 ± 9.0% [95% CI: 73.27–88.33] (\(n = 8\), Figure 1B). Under this experimental condition, the values of percent inhibition were considerably greater than the values of percent inhibition predicted by the Bliss independence (BI) theory (48.1 ± 5.7%, 95% CI: 43.33–52.87, \(n = 8\), \(p < 0.01\); Figure 1C).
2.2. Role of G Protein/Ca^{2+}-Activated K⁺ Channel Linkage in the Synergistic Effects

When procaterol (1 nM) was combined with tiotropium (1 nM), MCh (10 μM)-induced contraction was attenuated by 33.7 ± 5.3% [95% CI: 29.91–37.49] (n = 10, Figure 2A). In the presence of iberiotoxin (IbTX, 30 nM), the effects of this combination of procaterol (1 nM) with tiotropium (1 nM) were markedly attenuated to 13.2 ± 4.4% [95% CI: 9.52–16.88] (n = 8, p < 0.01, Figure 2A). This inhibitory effect of IbTX was concentration-dependent; in the presence of IbTX (3.0 and 10 nM) the effects of this combination of agents were attenuated to 26.7 ± 3.8% [95% CI: 23.52–29.88] (p < 0.05) and 19.0 ± 4.3% [95% CI: 15.40–22.60] (p < 0.01), respectively (each n = 8, Figure 2B). The inhibitory effect of IbTX (30 nM) was reversed to 32.8 ± 3.9% [95% CI: 29.54–36.06] (n = 8, not significant) in the presence of verapamil (1 μM) (Figure 2B). In contrast, the inhibitory effects of procaterol with tiotropium were markedly augmented to 52.9 ± 9.4% [95% CI: 45.04–60.76] in the presence of verapamil (1 μM) (n = 8, p < 0.05, Figure 2A). The stimulatory effect of verapamil was concentration-dependent; in the presence of verapamil (0.1 and 0.3 μM) the effects of this combination of these agents were augmented to 34.5 ± 5.3% [95% CI: 30.07–38.98] (not significant) and 42.8 ± 4.7% [95% CI: 38.87–46.73] (p < 0.05), respectively (each n = 8, Figure 2C). The effect of verapamil was decreased to 36.1 ± 6.0% [95% CI: 31.08–41.12] (n = 8, not significant) in the presence of IbTX (30 nM) (Figure 2C). Moreover, after the tissues were incubated with pertussis toxin (PTX, 1 μg/mg) to suppress Gi activity or with cholera toxin (CTX, 2 μg/mL) to increase Gs activity for six hours, the inhibitory effects of this combination of these two agents were markedly improved to 66.6 ± 9.7% [95% CI: 56.42–76.78] (n = 6, p < 0.01) and 70.8 ± 8.5% [95% CI: 61.88–79.72] (n = 6, p < 0.01), respectively (Figure 2A). Similar results were observed for salbutamol and tiotropium. The combination of salbutamol (10 nM) with tiotropium (1 nM) caused a 36.4 ± 6.1 percent inhibition of MCh (10 μM)-induced contraction [95% CI: 31.30–41.51] (n = 8, Figure 2D). This effect of a combination of these two agents was attenuated to 14.8 ± 4.8
percent inhibition [95% CI: 9.76–19.84] (n = 6, p < 0.01) in the presence of IbTX (30 nM); in contrast, this was increased to a 56.4 ± 7.3 percent inhibition (n = 6, p < 0.05) in the presence of verapamil (1 μM) (Figure 2D). Pre-exposure to PTX and CTX for six hours also enhanced the inhibitory effects of salbutamol with tiotropium. Values of percent inhibition were increased to 60.8 ± 8.1% [95% CI: 52.30–69.30] (n = 6, p < 0.01) and 65.6 ± 6.6% [95% CI: 58.67–72.53] (n = 6, p < 0.01), respectively (Figure 2D). When procaterol (1 nM) with atropine (1 nM) was applied to the Fura-2 loaded tissues pre-contracted by MCh (1 μM), $F_{340}/F_{380}$ (an indicator of concentration of intracellular Ca$^{2+}$) was decreased by 46.5 ± 5.2% [95% CI: 38.23–54.77] (n = 8, p < 0.01, Figure 2C,D). IbTX reduced the percent inhibition of $F_{340}/F_{380}$ induced by procaterol with atropine to 14.8 ± 4.4% [95% CI: 6.44–23.16] (n = 4, p < 0.01), on the other hand, IbTX with verapamil augmented the values of $F_{340}/F_{380}$ to 38.5 ± 5.9% [95% CI: 27.26–49.74] (n = 4, p < 0.01, Figure 2E,F).

**Figure 2.** Mechanisms of synergistic effects of the combination of β2-adrenergic receptor agonists with muscarinic receptor antagonists. (A) Values of percent inhibition of procaterol (1 nM) with tiotropium (1 nM) against MCh (1 μM)-induced contraction (control) in the presence of IbTX (30 nM), or verapamil (1 μM), and after incubation with pertussis toxin (1 μg/mL, PTX) and cholera toxin (2 μg/mL, CTX) for six hours; (B) Values of percent inhibition of procaterol with tiotropium against MCh-induced contraction in the presence of IbTX (30 nM), or verapamil (1 μM); (C) Values of percent inhibition of procaterol with tiotropium against MCh-induced contraction in the presence of verapamil (0.1–1.0 μM) without/with IbTX (30 nM); (D) Values of salbutamol (10 nM) with tiotropium (1 nM) against MCh (1 μM)-induced contraction under the same experimental conditions as 2A; (E) A typical record of $F_{340}/F_{380}$ demonstrating the effect of IbTX (30 nM) and verapamil (1 μM) on a combination of procaterol (1 nM) with atropine (1 nM) in the presence of MCh (1 μM); (F) Values of percent inhibition of $F_{340}/F_{380}$ in MCh (1 μM)-induced contraction under the condition of procaterol with atropine in the absence and presence of IbTX and verapamili. MCh: methacholine, IbTX: iberiotoxin, NS: not significant, *: p < 0.05, **: p < 0.01.
2.3. Role of Orthosteric Sites in the Effects of Muscarinic Receptor Antagonists

When atropine, tiotropium and glycopyrronium (0.0003–10 μM) were cumulatively applied to the tissues pre-contracted with MCh (1 and 10 μM), these agents inhibited MCh-induced contraction in a concentration-dependent manner, and complete inhibition was observed under these experimental conditions (Table 1). When the concentration of MCh was increased to 10 μM, these agents also caused a concentration-dependent inhibition, and complete relaxation was also observed at 0.3 μM of each agent (Figure 3A). Moreover, the complete relaxation was not attenuated even when the concentration of these agents were increased to more than 0.3 μM (Figure 3A). The concentration-inhibition curves for these agents against MCh (1 and 10 μM), the values of EC50 and the maximal effect of these curves for these agents under each experimental condition are summarized in Table 1. On the other hand, when MCh was cumulatively applied to the tissues, the value of EC50 was 0.6 ± 0.3 μM [95% CI: 0.26–0.68] (n = 6), and maximal response was observed at 100 μM (Figure 3B). In the concentration-response curves for MCh in the presence of atropine, tiotropium and glycopyrronium at each 10 nM, values of EC50 increased to 2.8 ± 0.9 [95% CI: 1.86–3.75] (n = 6), 3.9 ± 1.2 [95% CI: 2.64–5.16] (n = 6), 2.3 ± 0.7 μM [95% CI: 1.57–3.04] (n = 6), respectively (not significant), and the maximal contraction was not diminished under this experimental condition (Figure 3B).

![Figure 3](image-url)

**Figure 3.** Effects of a muscarinic receptor antagonist on muscarinic contraction via orthosteric sites. (A) Concentration-inhibition curves for atropine, tiotropium and glycopyrronium against MCh (10 μM); (B) Concentration-response curves for MCh (control) in the absence and presence of atropine, tiotropium and glycopyrronium (each 10 nM). MCh: methacholine.

| Muscarinic Receptor Antagonists | EC50 (nM)  | MCh  | Emax (%) |
|-------------------------------|-----------|------|----------|
|                               | Mean ± S.D. | 95% CI | Mean ± S.D. | 95% CI | Mean ± S.D. | Mean ± S.D. |
| Tiotropium                    | 3.3 ± 0.5  | 2.78–3.82 | 12.5 ± 3.2 * | 9.82–15.18 | 100 | 100 |
| Atropine                      | 5.7 ± 1.1  | 4.55–6.86 | 17.5 ± 5.9 * | 12.57–22.43 | 100 | 100 |
| Glycopyrronium                | 8.2 ± 1.1  | 7.05–9.36 | 19.2 ± 7.1 * | 13.26–25.14 | 100 | 100 |

* p < 0.05 vs. response to 1 μM MCh; Emax: maximal percent inhibition; 95% CI: 95% confidential interval.

2.4. Role of Allosteric Sites in the Effects of β2-Adrenergic Receptor Agonists

When procaterol and salbutamol were cumulatively applied to the tissues pre-contraction with MCh (1 and 10 μM), the maximal inhibition was observed for each experimental condition; the inhibitory effects of these agents were attenuated in a concentration-dependent manner at higher concentrations than the concentrations that produce the maximal effects (Figure 4A,B). Similar results were observed in the cumulative application of formoterol to MCh (10 μM)-induced contraction (Figure 5D). Procaterol caused almost complete relaxation (100% inhibition) of MCh (1 μM)-induced contraction, whereas, complete inhibition did not occur in other experimental conditions (Figure 4A,B and Figure 5D). On the other hand, when isoproterenol was cumulatively applied to the tissues...
pre-contracted with MCh (1 and 10 µM), it caused complete inhibition against MCh-induced
conditions; moreover, the inhibitory effects of isoproterenol were not attenuated at the higher
concentrations that produce the maximal effects, which is different from procaterol, salbutamol
and formoterol (Figures 4C and 5D). The concentration-inhibition curves for these agents against MCh
(1 and 10 µM)-induced contraction, the values of EC50 and the maximal inhibition are summarized
in Table 2.

Figure 4. Effects of β2-adrenergic receptor agonists on muscarinic contraction via allosteric
effects (efficacy modulation) in β2-adrenergic receptors. (A) A typical example of continuous
recording of cumulative applications of procaterol to the tissues pre-contracted by 10 µM MCh;
(B) Concentration-inhibition curves for procaterol and salbutamol against contraction induced by
MCh (10 µM); (C) Concentration-inhibition curves for isoproterenol against contraction induced by
MCh (1 and 10 µM). MCh: methacholine. **: p < 0.01.

Table 2. Pharmacological characteristics of β2-adrenergic receptor agonists.

| β2-Adrenergic Receptor Agonists | EC50 (nM)       | MCh               |                         |                         |
|--------------------------------|-----------------|-------------------|-------------------------|-------------------------|
|                                |                 | 1 µM (n = 6)      | 10 µM (n = 8)           |                         |
|                                | Mean ± S.D.     | 95% CI            | Mean ± S.D.             | 95% CI                  |
| Procaterol                     | 1.9 ± 0.6       | 1.17–2.43         | 8.3 ± 2.6 *             | 6.13–10.47              |
| Salbutamol                     | 18.6 ± 6.3      | 11.69–25.21       | 296.4 ± 90.6 **         | 228.21–335.59           |
| Formoterol                     | 0.7 ± 0.3       | 0.39–1.02         | 2.1 ± 0.3 **            | 1.85–2.35               |
| Isoproterenol                  | 308.1 ± 68.6    | 236.08–380.12     | 1736.4 ± 98.2 **        | 1654.48–1818.52         |

| β2-Adrenergic Receptor Agonists | Emax (%)        | MCh               |                         |                         |
|--------------------------------|-----------------|-------------------|-------------------------|-------------------------|
|                                |                 | 1 µM (n = 6)      | 10 µM (n = 8)           |                         |
|                                | Mean ± S.D.     | 95% CI            | Mean ± S.D.             | 95% CI                  |
| Procaterol                     | 97.6 ± 2.2      | 95.40–99.81       | 70.2 ± 9.3 **           | 62.42–77.98             |
| Salbutamol                     | 78.6 ± 8.4      | 69.78–87.42       | 51.0 ± 6.4 **           | 45.65–56.35             |
| Formoterol                     | 98.1 ± 1.6      | 96.42–99.78       | 71.0 ± 8.1 **           | 64.23–77.77             |
| Isoproterenol                  | 100             | 100               |                         |                         |

* p < 0.05, ** p < 0.01 vs. response to 1 µM MCh; Emax: maximal percent inhibition; 95% CI: 95% confidential interval.
In the presence of tiotropium (1 nM), concentration-inhibition curve for procaterol against MCh (10 µM) were not attenuated at higher concentrations than those concentrations than produce the maximal effects, unlike the effects of procaterol without tiotropium. Similar results were observed for salbutamol with tiotropium. Concentration-inhibition curves for salbutamol with tiotropium increased to 78.3 ± 6.6% [95% CI: 71.11–85.49].

### 2.5. Role of Allosteric Effects in the Synergistic Effects of β2-Adrenergic Receptor Agonists with Muscarinic Receptor Antagonists

Figure 5. Synergistic effects of a combination of β2-adrenergic receptor agonists with muscarinic receptor antagonists against muscarinic contraction via allosteric effects (affinity and efficacy modulation). Concentration-inhibition curves for procaterol (A) and salbutamol (B) against MCh (10 µM)-induced contraction in the absence and presence of tiotropium (1 nM); (C) Concentration-inhibition curves for procaterol against MCh (10 µM)-induced contraction in the absence and presence of atropine (1 nM); (D) Concentration-inhibition curves for formoterol against MCh (10 µM)-induced contraction in the absence and presence of glycopyrronium (1 nM). MCh: methacholine, (a): affinity, (b): efficacy, **: p < 0.01.

When tiotropium, atropine, and glycopyrronium (each 1 nM) were exposed to the tissues pre-contracted with MCh (10 µM) for 120 min, the maximal inhibition of tiotropium was 8.2 ± 2.1% (n = 10) [95% CI: 2.22–14.18], 6.8 ± 1.9% (n = 10) [95% CI: 1.39–12.20] and 6.2 ± 1.4% [95% CI: 2.22–10.18] (n = 10), respectively, for this extended period. Although these agents were slow to act, the time-dependent effects were modest under this experimental condition. Procaterol and salbutamol were cumulatively applied to the tissues pre-contracted with MCh (10 µM). MCh-induced contraction were significantly dissociated from the curves for procaterol in the absence of tiotropium. In the curves for procaterol with tiotropium, the values of EC50 were significantly decreased to 1.6 ± 0.4 nM [95% CI: 1.27–1.91] (n = 8, p < 0.01, Figure 5A). Moreover, in the curves for procaterol with tiotropium, maximal inhibition of the curves for procaterol was markedly increased to 94.3 ± 4.6% [95% CI: 90.45–98.15] (n = 8, p < 0.01; Figure 5A). The maximal effects of procaterol were not attenuated at higher concentrations than those concentrations than produce the maximal effects, unlike the effects of procaterol without tiotropium. Similar results were observed for salbutamol with tiotropium. Concentration-inhibition curves for salbutamol with tiotropium (1 nM) against MCh (10 µM) were also significantly dissociated from the curves for salbutamol without tiotropium. In the curves for salbutamol with tiotropium, the values of EC50 were significantly decreased to 12.8 ± 6.6 nM [95% CI: 7.22–18.12] (n = 8, p < 0.01; Figure 5B). Maximal inhibition of the curves for salbutamol with tiotropium increased to 78.3 ± 8.6% [95% CI: 71.11–85.49]; the maximal
effects of salbutamol were also not attenuated at higher concentrations than those concentrations that produce the maximal effects \((n = 8, p < 0.01; \text{Figure } 5\text{B})\). In the concentration-inhibition curves for procaterol with atropine \((1 \text{nM})\) against MCh \((10 \mu\text{M})\), the values of \(EC_{50}\) were significantly decreased to \(2.0 \pm 0.8 \text{nM} [95\% \text{CI}: 1.16–2.84] (n = 6, p < 0.01; \text{Figure } 5\text{C})\), and the maximal inhibition was increased to \(91.3 \pm 6.4\% [95\% \text{CI}: 84.58–98.02] (n = 6, p < 0.01; \text{Figure } 5\text{C})\). In the concentration-inhibition curves for formoterol with glycopyrronium \((1 \text{nM})\) against MCh \((10 \mu\text{M})\), the values of \(EC_{50}\) were significantly decreased to \(0.20 \pm 0.04 \text{nM} [95\% \text{CI}: 0.16–0.24] (n = 6, p < 0.01; \text{Figure } 5\text{D})\), and the maximal inhibition was increased to \(96.4 \pm 3.4\% [95\% \text{CI}: 92.81–99.97] (n = 6, p < 0.01; \text{Figure } 5\text{D})\). The maximal effect was not attenuated at higher concentrations than those concentrations that produced the maximal effect \((\text{Figure } 5\text{D})\), similar to the combination of procaterol and salbutamol with tiotropium.

### 2.6. Possible Mechanisms of cAMP-Independent Processes in the Synergistic Effect

Forskolin and db-cAMP, which are independent of \(\beta_2\)-adenrenergic receptors, caused a concentration-dependent suppression of MCh \((10 \mu\text{M})\)-induced contraction, and complete relaxation \((100\% \text{ inhibition})\) was observed for each experimental condition. The maximal effects of these agents were not attenuated at higher concentrations than those concentrations that produce the maximal effects in the absence and presence of tiotropium, unlike \(\beta_2\)-adrenergic receptor agonists. In the concentration-inhibition curves for forskolin and db-cAMP, \(EC_{50}\) was not significantly reduced in the present of tiotropium \((1 \text{nM})\) \((\text{Figure } 6\text{A,B})\), which is different to \(\beta_2\)-adrenergic receptor agonists. Under these experimental conditions, the values of \(EC_{50}\) were \(0.69 \pm 0.28 [95\% \text{CI: 0.40–0.98}]\) and \(0.41 \pm 0.18 \mu\text{M} [95\% \text{CI: 0.22–0.60}], \) respectively \((n = 6, \text{not significant, Figure } 6\text{A})\), and \(10.4 \pm 4.6 \mu\text{M} [95\% \text{CI: 5.57–15.23}] \) and \(8.1 \pm 3.3 \mu\text{M} [95\% \text{CI: 4.64–11.57}] \) \((n = 6, \text{not significant, Figure } 6\text{B})\), respectively.

![Figure 6](image)

**Figure 6.** The synergistic effect is not due to bypassing \(\beta_2\)-adrenergic receptors and blocking muscarinic receptors. Concentration-inhibition curves for forskolin \((\text{A})\) and db-cAMP \((\text{B})\) in the absence and presence of tiotropium \((1 \text{nM})\). \((\text{C})\) Concentration-inhibition curves for procaterol against MCh \((3 \mu\text{M})\)-induced contraction. The curve for procaterol against MCh \((10 \mu\text{M})\) with tiotropium \((1 \text{nM})\) is superimposed (ref. Figure 5\text{A}). \*: \(p < 0.05\).
2.7. Possible Involvement of Interaction between Muscarinic Receptor Antagonists and Allosteric Sites on β2-Adrenergic Receptors

When the concentration of MCh was decreased from 10 μM to 3 μM, MCh–induced contraction was attenuated by approximate 10% (Figure 3B). The effect of MCh (3 μM) was roughly equivalent to that of MCh (10 μM) with tiotropium (1 nM). In concentration-inhibition curves for procaterol against MCh (3 μM), the value of EC$_{50}$ were 50.8 ± 15.4 nM [95% CI: 34.64–66.97] (n = 6, p < 0.05), and the value of the maximal inhibition were 80.3 ± 7.8% [95% CI: 72.11–88.49] (n = 6, p < 0.05, Figure 6C). The maximal effects of procaterol against MCh (3 μM) without muscarinic receptor antagonists were attenuated at higher concentrations in a concentration-dependent manner. The curves for procaterol against MCh (3 μM) were significantly different from those curves for procaterol with tiotropium (1 nM) against MCh (10 μM) (Figure 6C).

3. Discussion

This study used physiological methods to demonstrate that G proteins/K$_{Ca}$ channel/VDC channel linkages are an essential process in the synergistic effects induced by crosstalk between β2-adrenergic and muscarinic M$_2$ receptors. Furthermore, allosteric effects play a functionally important role in the alteration of the response to β2-adrenergic receptor agonists and muscarinic receptor antagonists via crosstalk between these two GPCRs, i.e., (1) reduced responsiveness to β2-adrenergic receptor agonists (partial agonism); and (2) enhanced responsiveness to the combination of β2-adrenergic receptor agonists with muscarinic receptor antagonists (synergism).

The combination of β2-adrenergic receptor agonists (procaterol, salbutamol) with a muscarinic receptor antagonist (tiotropium) synergistically enhanced the relaxant effects against muscarinic contraction (Figure 1), consistent with previous reports using other β2-adrenergic receptor agonists (indacaterol, formoterol) and muscarinic receptor antagonists (glycopyrronium, aclidinium) [4,11,24,33]. Moreover, the combination of atropine with procaterol and the combination of glycopyrronium with formoterol produced synergistic effects (Figure 5C,D). Therefore, this phenomenon is probably universal, not specific to an agent related to these two receptors.

In airway smooth muscle tone, Ca$^{2+}$ signaling contributes to the intracellular processes in the downstream of these two GPCRs [6,8,34,35]. Suppression of K$_{Ca}$ channel activity enhances muscarinic contraction with an increase in Ca$^{2+}$ influx pass through VDC channels [17]. Ca$^{2+}$ dynamics due to K$_{Ca}$ channels [4,11] and Ca$^{2+}$ sensitization due to PKC contributes to the synergistic effects between β2-adrenergic receptor agonists and muscarinic receptor antagonists [24]. In this study, the effect of VDC channels was analyzed and whether the Ca$^{2+}$ dynamics due to K$_{Ca}$ channels is involved in this synergism was investigated. K$_{Ca}$ channel activity is associated with the functional antagonism between β2-adrenergic and muscarinic receptors [1,2,4]. K$_{Ca}$ channels are activated not only by protein kinase A (PKA) but also by G$_s$, which is coupled to β2-adrenergic receptors [36,37]. In contrast, these channels are inhibited by G$_i$, which is coupled to muscarinic M$_2$ receptors [1,4,38]. The synergistic effects of β2-adrenergic receptor agonists with muscarinic receptor antagonists were markedly augmented when G$_s$ was activated by cholera toxin and G$_i$ is inhibited by pertussis toxin (Figure 2A,D). These synergistic effects may be caused by β2-adrenergic receptor agonists/G$_s$ protein/K$_{Ca}$ channels’ stimulatory coupling and muscarinic M$_2$ receptors/G$_i$ protein/K$_{Ca}$ channels’ inhibitory coupling. Moreover, the synergistic effects were inhibited by IbTX, an inhibitor of K$_{Ca}$ channels, in a concentration-dependent manner (Figure 2A,B), indicating that activation of K$_{Ca}$ channels is involved in this phenomenon. In contrast, the synergistic effects were augmented by verapamil, an inhibitor of VDC channels, in a concentration-dependent manner, indicating that inactivation of VDC channels is involved in this phenomenon (Figure 2A,C). IbTX and verapamil were antagonistic to each other in the regulation of synergistic effects (Figure 2B,C), indicating that coupling between K$_{Ca}$ and VDC channels is involved in this phenomenon. IbTX inhibited a reduction in intracellular Ca$^{2+}$ concentration induced by procaterol with atropine, in contrast, verapamil reversed this effect of IbTX (Figure 2E,F), indicating that suppression of K$_{Ca}$ channels increases the concentration.
of intracellular Ca\(^{2+}\) via activation of VDC channels (Ca\(^{2+}\) dynamics due to \(K_{Ca}\) channels/VDC channels coupling). Activation of \(K_{Ca}\) channels causes membrane hyperpolarization, which deactivates VDC channels. This channel coupling enhances relaxation of airway smooth muscle [2,17]. Therefore, Ca\(^{2+}\) dynamics via these G proteins/\(K_{Ca}\) channel/VDC channel processes may contribute to the synergistic action (Figure 2). The functional antagonism to \(\beta_2\)-adrenergic receptors also may be mediated by muscarinic M\(_2\) receptors [39–41].

Allosteric affinity and efficacy modulation to muscarinic receptors and \(\beta_2\)-adrenergic receptors was examined using the concentration-inhibition curves for muscarinic receptor antagonists and \(\beta_2\)-adrenergic receptor agonists against muscarinic contraction (Figures 3 and 4) [4,42,43], and the intrinsic efficacy of muscarinic receptor antagonists and \(\beta_2\)-adrenergic receptor agonists was determined under these experimental conditions (Tables 1 and 2). Allosteric modulators alter association or dissociation rates of orthosteric ligands (affinity modulation) via acting allosteric sites. Allosteric effects operate intracellular responses and alter the signaling capacity (intrinsic efficacy) of orthosteric ligands (efficacy modulation) [30–32]. When agents act on their specific GPCRs at orthosteric sites without allosteric sites, the maximal response to agents as orthosteric ligands is not attenuated (Figure 7A,B) because an allosteric modulation does not occur (full agonism). In the functional antagonism (crosstalk) between \(\beta_2\)-adrenergic and muscarinic receptors, when agents act upon their specific GPCRs at both orthosteric and allosteric sites, partial agonism of \(\beta_2\)-adrenergic receptors is generated because response to agents as orthosteric ligands is altered by allosteric efficacy modulation (Figure 7A,C) [4,43].

To determine the involvement of orthosteric and allosteric sites in the relaxant action of muscarinic receptor antagonists against muscarinic contraction, affinity and efficacy modulation of these antagonists were examined using concentration-inhibition curves for these antagonists on a muscarinic receptor agonist. Muscarinic receptor antagonists, including atropine, tiotropium, and glycopyrroium, caused the maximal effect (complete inhibition) of muscarinic contraction, and the maximal effect was not attenuated even when higher concentrations of these antagonists were applied (Figure 3A, Table 1). Moreover, in the concentration-response curves for MCh with these antagonists, the values of EC\(_{50}\) were markedly increased without reducing the maximal response (Figure 3B). Since muscarinic receptor antagonists competitively inhibit the effects of a ligand on the receptor, these agents do not alter the signal capacity of orthosteric ligands via binding to allosteric sites [42,43]. Hence, muscarinic receptor antagonists do not cause efficacy modulation against orthosteric effects in muscarinic action, and allosteric sites on muscarinic receptors are not associated with muscarinic antagonism induced by these agents (Figure 7B) [42,43].

To determine the involvement of orthosteric and allosteric sites in the relaxant action of \(\beta_2\)-adrenergic receptor agonists against muscarinic contraction, affinity and efficacy modulation of these agonists were examined using concentration-inhibition curves for these agonists on a muscarinic receptor agonist. Isoproterenol completely antagonized muscarinic contraction, and the complete inhibition induced by isoproterenol was not attenuated (Figure 4C) at higher concentrations than those that produce maximal relaxation. Isoproterenol acts on orthosteric sites in \(\beta_2\)-adrenergic receptors and does not act on allosteric sites in these receptors (Figure 7A,C). Hence, isoproterenol behaves as a full agonist. In contrast, procaterol, salbutamol and formoterol incompletely antagonize muscarinic contraction (Figure 4A,B and Figure 5D), similar to indacaterol and salmeterol [4,11,44,45]. A lack of complete inhibition by \(\beta_2\)-adrenergic receptor agonists indicates a decrease in the signal capacity induced by efficacy modulation (an inhibition in response to orthosteric site via allosterism). At higher concentrations than those that produce the maximal relaxation, procaterol, salbutamol and formoterol caused a concentration-dependent contraction, unlike isoproterenol, suggesting that the primary effects (signal capacity) of these agents via orthosteric sites are reduced by efficacy modulation via binding to allosteric sites (Figure 7A,C). Therefore, in the \(\beta_2\)-adrenergic receptor agonists, except isoproterenol, intrinsic efficacy is attenuated by stimulating allosteric sites, indicating
that these agonists behave as allosteric modulators against β2-adrenergic receptors (partial agonists) (Figure 7A,B, Table 2) [4,11,44,45].

**Figure 7.** Involvement of allosteric effects (affinity and efficacy modulation) in response to β2-adrenergic receptor agonists and muscarinic receptor antagonists against muscarinic contraction. (A) A schema of affinity and efficacy modulation via allosteric sites shown in concentration-response curves for β2-adrenergic receptor agonists against muscarinic contraction; (B) Muscarinic receptor antagonists inhibit muscarinic action via acting on orthosteric sites on muscarinic receptors, independent of allosteric sites; (C) Full β2-adrenergic receptor agonists do not act on allosteric sites. In contrast, partial β2-adrenergic receptor agonists act not only on orthosteric sites, but also on allosteric sites on these receptors, and these agonists reduce the signal capacity (intrinsic efficacy) of an orthosteric ligand via efficacy modulation induced by operating upon allosteric sites; (D) Muscarinic receptor antagonists act on allosteric sites of β2-adrenergic receptors, and as a result affinity and efficacy of β2-adrenergic receptor agonists are enhanced, leading to the synergistically relaxant action of the combination of β2-adrenergic receptor agonists with muscarinic receptor antagonists via crosstalk of these two receptors. M: muscarinic receptors, β2: β2-adrenergic receptors, M2: muscarinic M2 receptors. (a): affinity, (b): efficacy, (c): signal capacity (intrinsic efficacy). Arrows: activation, dotted arrows: inhibition.

To determine the involvement of orthosteric and allosteric sites in this synergistic effect between β2-adrenergic receptor agonists and muscarinic receptor antagonists, affinity and efficacy modulation of β2-adrenergic receptor agonists with muscarinic receptor antagonists were examined using concentration-inhibition curves for these agonists on a muscarinic receptor agonist. Allosteric modulation occurs in the interaction mediated by ligands related to GPCRs [30–32]. When agents act not only on their specific GPCGs at orthosteric sites as orthosteric ligands, but also on other GPCRs at allosteric sites, synergism may be generated via affinity and efficacy modulation due to allosterism [4,15]. The combination of β2-adrenergic receptor agonists with muscarinic receptor antagonists may synergistically inhibit muscarinic contraction via allosterism (affinity and efficacy modulation) [4,15].
modulation). In the concentration-inhibition curves for procaterol, salbutamol and formoterol with muscarinic receptor antagonists (tiotropium, atropine, glycopyrronium), the values of EC\textsubscript{50} were markedly decreased; the maximal effects of these \(\beta_2\)-adrenergic receptor agonists were markedly augmented in each experimental condition (Figure 5). Muscarinic receptor antagonists may enhance affinity and efficacy of \(\beta_2\)-adrenergic receptor agonists, leading to synergistic effects on muscarinic contraction (Figure 7A,D). However, this synergistic effect may be due to inhibition of muscarinic contraction induced by muscarinic receptor antagonists. To determine whether this phenomenon is involved in the synergistic effect, affinity and efficacy modulation of \(\beta_2\)-adrenergic receptor agonists were examined using concentration-inhibition curves for these agents without muscarinic receptor antagonists under the condition of a lower concentration of MCh. MCh (10 \(\mu\)M)-induced contraction with 1 nM of atropine, tiotropium and glycopyrronium was roughly equivalent to MCh (3 \(\mu\)M)-induced contraction (Figure 3A,B). The concentration-inhibition curve for procaterol against MCh (3 \(\mu\)M)-induced contraction was no different from the curve for procaterol with tiotropium (1 nM) against MCh (10 \(\mu\)M)-induced contraction (Figure 6C). Therefore, this synergistic effect is created independently of the effects of muscarinic receptor antagonists on their receptors. Muscarinic receptor antagonists may operate not only upon orthosteric sites on muscarinic receptors, but also upon allosteric sites on \(\beta_2\)-adrenergic receptors, and these antagonists enhance both affinity and efficacy to \(\beta_2\)-adrenergic receptors; as a result, this synergism may be generated via crosstalk between the two GPCRs (Figure 7D).

To determine whether the downstream of \(\beta_2\)-adrenergic receptor is involved in the synergistic effect, similar experiments were carried out using cAMP-related agents independent \(\beta_2\)-adrenergic receptors. Forskolin and N6-dibutylyl cyclic AMP (db-cAMP), which are unrelated to \(\beta_2\)-adrenergic receptors, did not cause synergistic effects in the presence of tiotropium (Figure 6A,B), which is different to \(\beta_2\)-adrenergic receptor agonists with muscarinic receptor antagonists (Figure 5). In human bronchial smooth muscle, intracellular concentration of cAMP is associated with the synergism between \(\beta_2\)-adrenergic receptor agonists and muscarinic receptor antagonists [46]. However, adenylyl cyclase/cAMP/PKA processes may not directly contribute to the synergistic effects between these two agents, because forskolin and db-cAMP caused a modest effect on this synergism (Figure 6A,B). This result is similar to the phenomenon that \(G_s\) is more potent in \(K_{Ca}\) channel activation than PKA; \(K_{Ca}\) channels are markedly activated by \(G_s\) independent of PKA [37]. The \(\beta_2\)-adrenergic receptor/\(G_s\) pathway, and muscarinic M\textsubscript{2} receptor/\(G_i\) pathway may be essential to the synergism between these two agents.

4. Materials and Methods

4.1. Tissue Preparation and Tension Records

The methods were similar to those described previously [2,47,48]. Male Hartley guinea pigs (250–350 g) were killed by injection of an overdose of anesthetics (150 mg/kg pentobarbital i.p.), and tracheas were excised from the animals. The tracheal ring with three segments of cartilage was removed and placed horizontally in a 2-mL organ bath for isometric tension recording. Tracheal smooth muscle strips were incubated with 15 \(\mu\)M Fura-2/AM for about 2 h at room temperature (22–24 \(^\circ\)C). The non-cytotoxic detergent Pluronic F-127 (0.01% \(w/v\)) was added to increase the solubility of Fura-2/AM. The intensities of excitation fluorescence at 340 nm and 380 nm were measured after background subtraction by exposure of the mucosal side to excitation light. The ratio of \(F_{340}\) to \(F_{380}\) (\(F_{340}/F_{380}\)) was used as a relative indicator of intracellular \(Ca^{2+}\) concentration [6–8]. Strips were perfused with the normal bathing solution at a constant flow rate of 3.0 mL/min throughout the experiments. The non-cytotoxic detergent Pluronic F-127 (0.01% \(w/v\)) was added to increase the solubility of Fura-2/AM. The intensities of excitation fluorescence at 340 nm and 380 nm were measured after background subtraction by exposure of the mucosal side to excitation light. The ratio of \(F_{340}\) to \(F_{380}\) (\(F_{340}/F_{380}\)) was used as a relative indicator of intracellular \(Ca^{2+}\) concentration [6–8]. Strips were perfused with the normal bathing solution at a constant flow rate of 3.0 mL/min throughout the experiments. The normal bathing solution was composed of NaCl (137 mM), KHCO\textsubscript{3} (5.9 mM), CaCl\textsubscript{2} (2.4 mM), MgCl\textsubscript{2} (1.2 mM), and glucose (11.8 mM), bubbled with a mixture of 99% O\textsubscript{2} and 1% CO\textsubscript{2} (pH 7.4). After equilibrating the preparation in normal bathing solution, the experiments were started, and the temperature of the organ bath was maintained at 37 \(^\circ\)C. The resting tone was abolished by
the addition to indomethacin (1 µM) throughout the experiments. All animal procedures in this study were approved by the Animal Care and Use Committee, Kindai University Faculty of Medicine (identification code: KAME-22-007, 24 February 2011).

4.2. Analysis of Synergistic Effect

The synergistic effects of the combination of procaterol or salbutamol with tiotropium were evaluated using the Bliss independence (BI) theory. This model assumes that two or more agents act independently, with different modes and sites of action (Greco et al., 1995; Goldoni and Johansson, 2007), and is expressed by the following equation: 

\[ E(x, y) = E(x) + E(y) - E(x) \times E(y) \]

where \( E \) is the fractional effect, and \( x \) and \( y \) are the doses of two compounds in a combination experiment. If the combined experimental value is higher than the expected value, the interaction is synergistic. If it is lower, the interaction is antagonistic [24,49,50].

4.3. Experimental Protocols

Concentration-response curves were plotted by the cumulative addition of agents at 10 min for each concentration. To examine the effect of inhibited (uncoupled to the muscarinic M\(_2\) receptor) \( G_i \), the inhibitory G protein of adenylyl cyclase, via adenosine diphosphate (ADP) ribosylation of the \( \alpha \)-subunit of \( G_i \) protein, the strips of tracheal smooth muscle were incubated with 1 µg/mL pertussis toxin (PTX) for 6 h and then the PTX was washed out. To examine the effects of activated \( G_s \), the stimulatory G protein of adenylyl cyclase coupled to \( \beta_2 \)-adrenergic receptors, via ADP ribosylation of the \( \alpha \)-subunit of \( G_s \) protein, the tissues were incubated with 2 µg/mL cholera toxin (CTX) for 6 h and then the CTX was washed out. The involvement of \( K_{Ca} \) channels and VDC channels was examined by application of iberiotoxin (IbTX), a potent selective inhibitor of \( K_{Ca} \) channels, and verapamil, a selective inhibitor of VDC channels. To examine allosteric effects (alteration of intrinsic efficacy of an orthosteric ligand: efficacy modulation) in the relaxant action of \( \beta_2 \)-adrenergic receptor agonists on muscarinic contraction were cumulatively applied to the tissues pre-contracted by methacholine (MCh, 1 and 10 µM). Moreover, to examine allosteric effects (affinity and efficacy modulation) in the relaxant action of the combination of \( \beta_2 \)-adrenergic receptor agonists with muscarinic receptors antagonists against muscarinic contraction, procaterol and salbutamol were cumulatively applied to the tissues pre-contracted by MCh (10 µM) in the absence and presence of muscarinic receptor antagonists (1 nM). The concentration-inhibition curves for \( \beta_2 \)-adrenergic receptor agonists were analyzed for each experimental condition. Time-matched control tissues were treated similarly to the test tissues, but exposed continuously to the normal bathing solution (sham incubation) instead of agents. Procaterol, salbutamol, and formoterol were used as \( \beta_2 \)-adrenergic receptor agonists. Atropine, tiotropium, and glycopyrronium were used as muscarinic receptor antagonists. Forskolin (a direct activator of adenylyl cyclase) and N6-dibutyryl cyclic AMP (db-cAMP, an analog of cAMP) were used as cAMP-related agents independent of \( \beta_2 \)-adrenergic receptors.

4.4. Materials

MCh, indomethacin, procaterol, salbutamol, isoproterenol, formoterol, atropine, and glycopyrronium were obtained from Wako pure Chemical Industries (Osaka, Japan). IbTX was obtained from Peptide Institute (Osaka, Japan). Tiotropium, verapamil, PTX, CTX, forskolin, db-cAMP and indomethacin were obtained from Sigma (St. Louis, MO, USA).

4.5. Statistical Analysis

All data are expressed as the mean ± standard deviation (SD) with 95% confidence interval (CI). The response to an agent is described as a percentage of the maximal response. The effect of relaxant agents on MCh-induced contraction is expressed as percent inhibition by taking the control response to MCh (1 or 10 µM) for each experimental condition as 100%. The response to MCh was described as the percent contraction by taking the maximal contraction under the control condition as 100%. Values of
the concentration of agents that produced a 50% response (EC$_{50}$) of contraction were determined from the linear portion of each concentration-response curve. Statistical significance was assessed by unpaired Student’s t-test, one-way analysis of variance and the Dunnett test. A probability below 0.05 ($p < 0.05$) was considered to be significant.

5. Conclusions

Combining of $\beta_2$-adrenergic receptor agonists with muscarinic receptor antagonists causes a synergistic inhibition against muscarinic contraction of airway smooth muscle. The $G$ proteins/$K_{Ca}$ channel/VDC channel linkage is a key molecule for this synergism, and allosteric GPCRs modulation induced by crosstalk between these two receptors plays a fundamental role in this phenomenon (Figure 8). Observations obtained from guinea pig trachea may have limited clinical relevance. However, muscarinic and $\beta_2$-adrenergic action is not so different, not only between guinea pig trachea [4,11,24] and human bronchus [46], but also between guinea pig [47] and human trachea [48]. $K_{Ca}$ channels are densely distributed on the airway smooth muscle in various mammals including humans; the electrical characteristics of these channels are no different between these species [51,52]. These results provide evidence that inhalation of a combined $\beta_2$-adrenergic receptor agonist and a muscarinic antagonist causes greater bronchodilation than monotherapy in asthma and COPD [25,27–29]. The $K_{Ca}$ channels/VDC channels coupling may also be responsible for $\beta_2$-adrenergic desensitization [53] and airway remodeling [54]. Hence, elucidation of the mechanisms of this synergism (crosstalk) may contribute to the development of novel bronchodilators for asthma and COPD [4,11,55].

**Figure 8.** Possible clinical relevance of the synergistically relaxant effects between $\beta_2$-adrenergic receptor agonists and muscarinic receptor antagonists. This synergism is caused by crosstalk based on allosteric GPCR modulation via $G$ proteins ($G_s$, $G_i$)/$K_{Ca}$ channel/VDC channel processes. Since this synergism causes greater bronchodilation, combining two agents may be beneficial to therapy for asthma and COPD. GPCR: $\beta_2$-adrenergic receptor agonist and a muscarinic receptor antagonist. Gs: the stimulatory $G$ protein of adenylyl cyclase coupled to $\beta_2$-adrenergic receptors, Gi: the inhibitory $G$ protein of adenylyl cyclase coupled to M2 receptors, G: the stimulatory $G$ protein of adenylyl cyclase coupled to $\beta_2$-adrenergic receptors, K: large-conductance Ca$^{2+}$-activated K$^+$ channels, VDC: L-type voltage-dependent Ca$^{2+}$ channels. Arrows: activation, dotted arrows: inhibition.

**Author Contributions:** Participated in research design: H.K.; Conducted experiments: H.K., T.I.; Contributed new reagents or analytic tools: O.N., Y.H., Y.T.; Performed data analysis: Y.N.

**Funding:** This work is supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (H.K. #25461201), and by Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan).

**Acknowledgments:** We thank Eriko Kira (Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine) for her technical assistance.
Conflicts of Interest: This work was partly supported by Otsuka Pharmaceutical Co., Ltd. (Hiroaki Kume), and this study was funded, in part, by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (Hiroaki Kume #25461201). The funding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

1. Kume, H.; Graziano, M.P.; Kotlikoff, M.I. Stimulatory and inhibitory regulation of calcium-activated potassium channels by guanine nucleotide-binding proteins. Proc. Natl. Acad. Sci. USA 1992, 89, 11051–11055. [CrossRef] [PubMed]

2. Kume, H.; Mikawa, K.; Takagi, K.; Kotlikoff, M.I. Role of G proteins and KCa channels in the muscarinic and β-adrenergic regulation of airway smooth muscle. Am. J. Physiol. 1995, 268, L221–L229. [CrossRef] [PubMed]

3. Kume, H. RhoA/Rho-kinase as a therapeutic target in asthma. Curr. Med. Chem. 2008, 15, 2876–2885. [CrossRef] [PubMed]

4. Kume, H.; Fukunaga, K.; Oguma, T. Research and development of bronchodilators for asthma and COPD with a focus on G protein/KCa channel linkage and β2-adrenergic intrinsic efficacy. Pharmacol. Ther. 2015, 156, 75–89. [CrossRef] [PubMed]

5. Uehata, M.; Ishizaki, T.; Satoh, H.; Ono, T.; Kawahara, T.; Morishita, T.; Tamakawa, H.; Yamagami, K.; Inui, J.; Maekawa, M.; et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997, 389, 990–994. [CrossRef] [PubMed]

6. Ito, S.; Kume, H.; Honjo, H.; Kodama, I.; Yamaki, K.; Hayashi, H. Possible involvement of Rho kinase in Ca2+ sensitization and mobilization by MCh in tracheal smooth muscle. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 280, L1218–L1224. [CrossRef] [PubMed]

7. Kojima, K.; Kume, H.; Ito, S.; Oguma, T.; Shiraki, A.; Kondo, M.; Ito, Y.; Shimokata, K. Direct effects of hydrogen peroxide on airway smooth muscle tone: Roles of Ca2+ influx and Rho-kinase. Eur. J. Pharmacol. 2007, 556, 151–156. [CrossRef] [PubMed]

8. Shiraki, A.; Kume, H.; Oguma, T.; Makino, Y.; Ito, S.; Shimokata, K.; Honjo, H.; Kamiya, K. Role of Ca2+ mobilization and Ca2+ sensitization in 8-iso-PGF2α-induced contraction in airway smooth muscle. Clin. Exp. Allergy 2009, 39, 236–245. [CrossRef] [PubMed]

9. Bai, Y.; Sanderson, M.J. The contribution of Ca2+ signaling and Ca2+ sensitivity to the regulation of airway smooth muscle contraction is different in rats and mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009, 296, L947–L958. [CrossRef] [PubMed]

10. Mahn, K.; Ojo, O.O.; Chadwick, G.; Aaronson, P.I.; Ward, J.P.; Lee, T.H. Ca2+ homeostasis and structural and functional remodeling of airway smooth muscle in asthma. Thorax 2010, 65, 547–552. [CrossRef] [PubMed]

11. Kume, H. Ca2+ dynamics and Ca2+ sensitization in the regulation of airway smooth muscle tone. In Muscle Cell and Tissue; Sakuma, K., Ed.; INTECH: Rijeka, Croatia, 2015; pp. 289–330.

12. Kotlikoff, M.I. Potassium channels in airway smooth muscle: A tale of two channels. Pharmacol. Ther. 1993, 58, 1–12. [CrossRef]

13. Ghatta, S.; Nimmagadda, D.; Xu, X.; O’Rourke, S.T. Large-conductance calcium-activated potassium channels: Structural and functional implications. Pharmacol. Ther. 2006, 110, 103–116. [CrossRef] [PubMed]

14. Kume, H. Large-conductance calcium-activated potassium channels. In Calcium Signaling in Airway Smooth Muscle Cells; Wang, Y.X., Ed.; Springer: New York, NY, USA, 2013; pp. 49–83.

15. Kume, H.; Ito, S. Role of large-conductance calcium-activated potassium channels on airway smooth muscle in physiological and pathological conditions. In Potassium Channels in Health and Disease; Kume, H., Ed.; Nova Science Publishers: New York, NY, USA, 2017; pp. 41–120.

16. Wang, Y.X.; Fleischmann, B.K.; Kotlikoff, M.I. Modulation of maxi-K+ channels by voltage-dependent Ca2+ channels and methacholine in single airway myocytes. Am. J. Physiol. 1997, 272, C1151–C1159. [CrossRef] [PubMed]

17. Kume, H.; Ishikawa, T.; Oguma, T.; Ito, S.; Shimokata, K.; Kotlikoff, M.I. Involvement of Ca2+ mobilization in tachyphylaxis to β-adrenergic receptors in trachealis. Am. J. Respir. Cell Mol. Biol. 2003, 29, 359–366. [CrossRef] [PubMed]
18. Bonnet, S.; Archer, S.L. Potassium channel diversity in the pulmonary arteries and pulmonary veins: Implications for regulation of the pulmonary vasculature in health and during pulmonary hypertension. *Pharmacol. Ther.* 2007, 115, 56–69. [CrossRef] [PubMed]

19. Deshpande, D.A.; Wang, W.C.; McIlmoyle, E.L.; Robinett, K.S.; Schillinger, R.M.; An, S.S.; Sham, J.S.; Liggett, S.B. Bitter taste receptors on airway smooth muscle bronchodilate by localized calcium signaling and reverse obstruction. *Nat. Med.* 2010, 16, 1299–1304. [CrossRef] [PubMed]

20. Ohyu, S.; Kito, H.; Hatano, N.; Muraki, K. Recent advances in therapeutic strategies that focus on the regulation of ion channel expression. *Pharmacol. Ther.* 2016, 160, 11–43. [CrossRef] [PubMed]

21. Calzetta, L.; Matera, M.G.; Cazzola, M. Pharmacological interaction between LABAs and LAMAs in the airways: Optimizing synergy. *Eur. J. Pharmacol.* 2015, 761, 168–173. [CrossRef] [PubMed]

22. Mukherjee, S.; Trice, J.; Shinde, P.; Willis, R.E.; Pressley, T.A.; Perez-Zoghbi, J.F. Ca$^{2+}$ oscillations, Ca$^{2+}$ sensitization, and contraction activated by protein kinase C in small airway smooth muscle. *J. Gen. Physiol.* 2013, 141, 165–178. [CrossRef] [PubMed]

23. Dixon, R.E.; Santana, L.F. A Ca$^{2+}$- and PKC-driven regulatory network in airway smooth muscle. *J. Gen. Physiol.* 2013, 141, 161–164. [CrossRef] [PubMed]

24. Fukunaga, K.; Kume, H.; Oguma, T.; Shigemori, W.; Tohda, Y.; Ogawa, E.; Nakano, Y. Involvement of Ca$^{2+}$ signaling in the synergistic effects between muscarinic receptor antagonists and β$_2$-adrenoceptor agonists in airway smooth muscle. *Int. J. Mol. Sci.* 2016, 17, 1590. [CrossRef] [PubMed]

25. The Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2017. Available online: http://goldcopd.org (accessed on 20 December 2017).

26. Dale, P.R.; Cernecke, H.; Schmidt, M.; Dowling, M.R.; Charlton, S.J.; Pieper, M.P.; Michel, M.C. The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease. *Curr. Opin. Pharmacol.* 2014, 16, 31–42. [CrossRef] [PubMed]

27. Wedzicha, J.A.; Decramer, M.; Ficker, J.H.; Niewoehner, D.E.; Sandstrom, T.; Taylor, A.F.; D’Andrea, P.; Arrasate, C.; Chen, H.; Banerji, D. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): A randomised, double-blind, parallel-group study. *Lancet Respir. Med.* 2013, 1, 199–209. [CrossRef]

28. Decramer, M.; Anzueto, A.; Kerwin, E.; Kaelin, T.; Richard, N.; Crater, G.; Tabberer, M.; Harris, S.; Church, A. Efficacy and safety of umclidinium plus vilanterol versus tiotropium, vilanterol, or umclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: Results from two multicentre, blinded, randomised controlled trials. *Lancet Respir. Med.* 2014, 2, 472–486. [CrossRef]

29. Buhl, R.; Maltais, F.; Abrahams, R.; Bjerner, L.; Derom, E.; Ferguson, G.; Flezar, M.; Hebert, J.; McGarvey, L.; Pizzichini, E.; et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). *Eur. Respir. J.* 2015, 45, 969–979. [CrossRef] [PubMed]

30. Conn, P.J.; Christophopolous, A.; Lindsley, C.W. Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders. *Nat. Rev. Drug Discov.* 2009, 8, 41–54. [CrossRef] [PubMed]

31. Kenakin, T.P. 7TM receptor allostery: Putting numbers to shapeshifting proteins. *Trends Pharmacol. Sci.* 2009, 30, 460–469. [CrossRef] [PubMed]

32. Kenakin, T.; Christophopolous, A. Signalling bias in new drug discovery: Detection, quantification and therapeutic impact. *Nat. Rev. Drug Discov.* 2013, 12, 205–216. [CrossRef] [PubMed]

33. Cazzola, M.; Calzetta, L.; Page, C.P.; Rogliani, P.; Facchini, F.; Gavaldà, A.; Matera, M.G. Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. *Eur. J. Pharmacol.* 2014, 745, 135–143. [CrossRef] [PubMed]

34. Oguma, T.; Kume, H.; Ito, S.; Takeda, N.; Honjo, H.; Kodama, I.; Shimokata, K.; Kamiya, K. Involvement of reduced sensitivity to Ca$^{2+}$ in β-adrenergic action on airway smooth muscle. *Clin. Exp. Allergy* 2006, 36, 183–191. [CrossRef] [PubMed]

35. Kume, H.; Takeda, N.; Oguma, T.; Ito, S.; Kondo, M.; Ito, Y.; Shimokata, K. Sphingosine 1-phosphate causes airway hyper-reactivity by Rho-mediated myosin phosphatase inactivation. *J. Pharmacol. Exp. Ther.* 2007, 320, 766–773. [CrossRef] [PubMed]

36. Kume, H.; Takai, A.; Tokuno, H.; Tomita, T. Regulation of Ca$^{2+}$-dependent K$^{+}$-channel activity in tracheal myocytes by phosphorylation. *Nature* 1989, 341, 152–154. [CrossRef] [PubMed]
37. Kume, H.; Hall, I.P.; Washabau, R.J.; Takagi, K.; Kotlikoff, M.I. β-Adrenergic agonists regulate \( K_{Ca} \) channels in airway smooth muscle by cAMP-dependent and -independent mechanisms. J. Clin. Investig. 1994, 93, 371–379. [CrossRef] [PubMed]

38. Kume, H.; Kotlikoff, M.I. Muscarinic inhibition of single \( K_{Ca} \) channels in smooth muscle cells by a pertussis-sensitive G protein. Am. J. Physiol. 1991, 261, C1204–C1209. [CrossRef] [PubMed]

39. Sarria, B.; Naline, E.; Zhang, Y.; Cortijo, J.; Molimard, M.; Moreau, J.; Therond, P.; Advenier, C.; Morcillo, E.J. Muscarinic M2 receptors in acetylcholine-isoproterenol functional antagonism in human isolated bronchus. Am. J. Physiol. Lung Cell. Mol. Physiol. 2002, 283, L1125–L1132. [CrossRef] [PubMed]

40. Matsui, M.; Griffin, M.T.; Shehnaz, D.; Taketo, M.M.; Ehlert, F.J. Increased relaxant action of forskolin and isoproterenol against muscarinic agonist-induced contractions in smooth muscle from M2 receptor knockout mice. J. Pharmacol. Exp. Ther. 2003, 305, 106–113. [CrossRef] [PubMed]

41. Semenov, I.; Wang, B.; Herlihy, J.T.; Brenner, R. BK channel \( \beta1 \) subunits regulate airway contraction secondary to \( M_2 \) muscarinic acetylcholine receptor mediated depolarization. J. Physiol. 2011, 589, 1803–1817. [CrossRef] [PubMed]

42. Kenakin, T. Allosteric theory: Taking therapeutic advantage of the malleable nature of GPCRs. Curr. Neuropsychopharmacol. 2007, 5, 149–156. [CrossRef] [PubMed]

43. Melancon, B.J.; Hopkins, C.R.; Wood, M.R.; Emmitte, K.A.; Niswender, C.M.; Conn, P.J.; Lindsley, C.W. Allosteric modulation of seven transmembrane spanning receptors: Theory, practice, and opportunities for central nervous system drug discovery. J. Med. Chem. 2012, 55, 1445–1464. [CrossRef] [PubMed]

44. Hanania, N.A.; Sharafkhaneh, A.; Barber, R.; Dickey, B.F. β-agonist intrinsic efficacy: Measurement and clinical significance. Am. J. Respir. Crit. Care Med. 2002, 165, 1353–1358. [CrossRef] [PubMed]

45. Kume, H. Clinical use of \( \beta_2 \)-adrenergic receptor agonists based on their intrinsic efficacy. Allergol. Int. 2005, 54, 89–97. [CrossRef]

46. Cazzola, M.; Calzetta, L.; Puxeddu, E.; Ora, J.; Facciolo, F.; Rogliani, P.; Matera, M.G. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. Respir. Res. 2016, 17, 70. [CrossRef] [PubMed]

47. Kume, H.; Takagi, K. Inhibitory effects of \( G_s \) on desensitization of \( \beta \)-adrenergic receptors in tracheal smooth muscle. Am. J. Physiol. 1997, 273, L556–L564. [CrossRef] [PubMed]

48. Kume, H.; Takagi, K. Inhibition of \( \beta \)-adrenergic desensitization by \( K_{Ca} \) channels in human trachealis. Am. J. Respir. Crit. Care Med. 1999, 159, 452–460. [CrossRef] [PubMed]

49. Greco, W.R.; Bravo, G.; Parsons, J.C. The search for synergy: A critical review from a response surface perspective. Pharmacol. Rev. 1995, 47, 331–385. [PubMed]

50. Goldoni, M.; Johansson, C. A mathematical approach to study combined effects of toxicants in vitro: Evaluation of the bliss independence criterion and the loewe additivity model. Toxicol. In Vitro 2007, 21, 759–769. [CrossRef] [PubMed]

51. Kume, H.; Takagi, K.; Satake, T.; Tokuno, H.; Tomita, T. Effects of intracellular pH on calcium-activated potassium channels in rabbit tracheal smooth muscle. J. Physiol. 1990, 424, 445–457. [CrossRef] [PubMed]

52. Snetkov, V.A.; Hirst, S.J.; Twort, C.H.; Ward, J.P. Potassium currents in human freshly isolated bronchial smooth muscle cells. Br. J. Pharmacol. 1995, 115, 1117–1125. [CrossRef] [PubMed]

53. Ikenouchi, T.; Kume, H.; Oguma, T.; Makino, Y.; Shiraki, A.; Ito, Y.; Shimokata, K. Role of \( Ca^{2+} \) mobilization in desensitization of \( \beta \)-adrenoceptors by platelet-derived growth factor in airway smooth muscle. Eur. J. Pharmacol. 2008, 591, 259–265. [CrossRef] [PubMed]

54. Girodet, P.O.; Dournes, G.; Thumerel, M.; Begueret, H.; Dos Santos, P.; Ozier, A.; Dupin, I.; Trian, T.; Montaudon, M.; Laurent, F.; et al. Calcium channel blocker reduces airway remodeling in severe asthma: A proof-of-concept study. Am. J. Respir. Crit. Care Med. 2015, 191, 876–883. [CrossRef] [PubMed]

55. Kume, H. Research and development for anti-asthmatic agents with a focus on phenotype changing by \( Ca^{2+} \) signaling in airway smooth muscle cells. In Frontiers in Clinical Drug Research—Anti Allergy Agents; Rahman, A.U., Ed.; Bentham: Sharjah, UAE, 2018; Volume 3, pp. 116–181. [CrossRef] [PubMed]